Biomind Labs Inc.
BMND
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.12% | -46.48% | -68.48% | -83.57% | -89.05% |
| Depreciation & Amortization | 0.00% | 0.00% | -54.17% | -100.00% | -79.82% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.32% | -69.82% | -73.06% | -82.41% | -85.74% |
| Operating Income | 29.32% | 69.82% | 73.06% | 82.41% | 85.74% |
| Income Before Tax | 72.53% | 41.26% | 57.07% | 48.94% | 86.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.53% | 41.26% | 57.07% | 48.94% | 86.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.53% | 41.26% | 57.07% | 48.94% | 86.41% |
| EBIT | 29.32% | 69.82% | 73.06% | 82.41% | 85.74% |
| EBITDA | 24.85% | 70.24% | 73.31% | 82.66% | 86.76% |
| EPS Basic | 76.47% | 41.67% | 56.90% | 49.30% | 86.29% |
| Normalized Basic EPS | 72.73% | 40.00% | 55.56% | 48.89% | 85.71% |
| EPS Diluted | 76.47% | 41.67% | 56.90% | 49.30% | 86.29% |
| Normalized Diluted EPS | 72.73% | 40.00% | 55.56% | 48.89% | 85.71% |
| Average Basic Shares Outstanding | 3.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 3.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |